Insider Selling: X4 Pharmaceuticals (NASDAQ:XFOR) CFO Sells $33,653.62 in Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO David Kirske sold 11,767 shares of the stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $2.86, for a total value of $33,653.62. Following the sale, the chief financial officer directly owned 155,983 shares in the company, valued at $446,111.38. This trade represents a 7.01% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

X4 Pharmaceuticals Stock Up 1.4%

XFOR stock opened at $2.81 on Thursday. The company has a quick ratio of 11.02, a current ratio of 11.30 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $278.61 million, a PE ratio of -2.34 and a beta of 0.46. X4 Pharmaceuticals, Inc. has a twelve month low of $2.70 and a twelve month high of $4.83. The stock has a 50-day simple moving average of $3.74 and a two-hundred day simple moving average of $3.95.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05. X4 Pharmaceuticals had a negative return on equity of 63.05% and a negative net margin of 568.80%.The firm had revenue of $8.81 million for the quarter, compared to analysts’ expectations of $2.42 million. On average, equities analysts predict that X4 Pharmaceuticals, Inc. will post -0.67 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. Wells Fargo & Company initiated coverage on shares of X4 Pharmaceuticals in a report on Friday, July 10th. They issued an “overweight” rating and a $11.00 price target on the stock. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, X4 Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $11.25.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of XFOR. Empery Asset Management LP purchased a new stake in X4 Pharmaceuticals in the fourth quarter valued at approximately $35,804,000. Perceptive Advisors LLC grew its stake in X4 Pharmaceuticals by 6.7% in the 1st quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock worth $27,826,000 after buying an additional 423,196 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of X4 Pharmaceuticals in the 2nd quarter worth $917,000. Bank of America Corp DE increased its holdings in shares of X4 Pharmaceuticals by 321.3% in the 1st quarter. Bank of America Corp DE now owns 150,676 shares of the company’s stock worth $622,000 after buying an additional 114,915 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of X4 Pharmaceuticals during the 2nd quarter valued at $313,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by immune and hematologic dysfunction. The company’s research centers on the CXCR4 biological pathway, which regulates the movement and retention of certain immune cells in the bone marrow and other tissues.

X4’s primary product is XOLREMDI (mavorixafor), an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for use in people aged 12 and older with WHIM syndrome.